Benzinga

Benzinga

Benzinga

sábado, agosto 22

Prime Medicine Inc

PRMENASDAQ
Trade with Public
Trade with Public
$3.39
0.154.63%
al cierre: Aug 21, 5:00 PM EST
$3.39
N/A
After hour: 7:23 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadDividendosCompararOpcionesInforme de acciones

Prime Medicine Analyst Price Targets

Wall Street analyst price targets and consensus rating for Prime Medicine (PRME).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

2S.Buy
10Buy
2Hold
Consensus RatingBuy# Analysts14Avg. Consensus PT$11Upside to Avg. PT+234.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 19, 2026BMO CapitalDavid LebowitzInitiateOutperform$9
Aug 10, 2026HC Wainwright & Co.Arthur HeMaintainedBuy$8
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9

BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target

HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.
Benzinga Newsdesk

This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday

Top Wall Street analysts upgraded Prime Medicine, Inc and Casey's General Stores Inc, and upgraded Warner Bros Discovery Inc with price targets.
Avi Kapoor

PRO
HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target

HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $8 price target.
Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $11

Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $11.
Benzinga Newsdesk

PRO
LifeSci Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $6

LifeSci Capital initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $6.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved